America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
How does the AOH1996 molecule specifically target cancer cells compared to normal cells?
**Interview with Dr. Linda Malkas: A Breakthrough in Targeted Chemotherapy**
**Editor:** Welcome, Dr. Malkas! Thank you for joining us today to discuss this exciting development in cancer treatment. Can you begin by explaining how the AOH1996 molecule works to target cancer cells?
**Dr. Malkas:** Thank you for having me! AOH1996 operates by specifically targeting the cancer variant of PCNA, which is critical for DNA replication and tumor growth. You can think of PCNA as an airport hub—where planes represent various cellular processes. Our drug acts like a blizzard that disrupts operations at this hub, effectively stopping the flow of planes, or in this case, halting the growth and replication of cancer cells while leaving normal cells largely unaffected.
**Editor:** That’s a fascinating analogy! Can you tell us more about the types of cancers this drug has shown promising results against?
**Dr. Malkas:** Certainly! Our research has indicated that AOH1996 has been effective in treating a variety of cancers, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. Over the past two decades, we have conducted extensive studies, and the molecule has demonstrated selective toxicity toward cancer cells across more than 70 different cancer cell lines.
**Editor:** It sounds like this research has immense potential. What are the next steps for AOH1996 after these promising results in the lab?
**Dr. Malkas:** The next step is to advance our findings into clinical trials involving human participants. This is a crucial phase where we can assess the drug’s efficacy and safety in a real-world setting. If successful, it could pave the way for a new, targeted approach to chemotherapy, providing hope to many patients battling cancer.
**Editor:** It must be rewarding to see two decades of hard work come to fruition. How do you think this development could change the landscape of cancer treatment?
**Dr. Malkas:** We believe that AOH1996 could significantly alter the way we approach cancer treatment. Targeted therapies aim to minimize harm to healthy cells while intensifying the attack on cancer cells, which can lead to fewer side effects and better outcomes for patients. This tailored approach may represent a new frontier in oncology.
**Editor:** Thank you, Dr. Malkas, for sharing your insights about this groundbreaking research. We look forward to hearing more as clinical trials progress!
**Dr. Malkas:** Thank you! It’s an exciting time for cancer research, and I appreciate the opportunity to discuss our work.